193 related articles for article (PubMed ID: 10690631)
1. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
2. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
7. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM; Clark GM; Fuqua SA; Yu YY; Allred DC
Cancer Res; 1994 Jul; 54(14):3752-7. PubMed ID: 8033095
[TBL] [Abstract][Full Text] [Related]
8. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
10. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study.
Ostrowski JL; Sawan A; Henry L; Wright C; Henry JA; Hennessy C; Lennard TJ; Angus B; Horne CH
J Pathol; 1991 May; 164(1):75-81. PubMed ID: 2056391
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
[TBL] [Abstract][Full Text] [Related]
12. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.
Tökés AM; Hortoványi E; Csordás G; Kulka J; Mózes G; Hatalyák A; Kádár A
Anticancer Res; 1999; 19(1A):175-9. PubMed ID: 10226540
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of p53 protein expression in breast carcinomas.
Hurlimann J
Pathol Res Pract; 1993 Nov; 189(9):996-1003. PubMed ID: 8302733
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and survival analysis of invasive ductal carcinoma of the breast in Bandung, Indonesia.
Hernowo BS; Yukawa M; Asaka K; Fujimori T; Maeda S; Mukawi TY
Kobe J Med Sci; 1995 Aug; 41(4):95-112. PubMed ID: 8904161
[No Abstract] [Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
